Viromed Medical AG (Q11) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Viromed Medical AG (Q11) has a cash flow conversion efficiency ratio of -0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.12 Million ≈ $-11.83 Million USD) by net assets (€269.20 Million ≈ $314.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Viromed Medical AG liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Viromed Medical AG - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Viromed Medical AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Viromed Medical AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viromed Medical AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jetwell Computer Co Ltd
TWO:3147
|
0.407x |
|
eQ Oyj
HE:EQV1V
|
0.103x |
|
Blockchain Group SA
PA:ALTBG
|
0.070x |
|
Korea Line
KO:005880
|
0.046x |
|
Rapid7 Inc
NASDAQ:RPD
|
0.228x |
|
Beijing Zhongkehaixun Digital S T
SHE:300810
|
-0.106x |
|
Unipar Carbocloro S.A
SA:UNIP3
|
0.098x |
|
Deutsche Rohstoff AG
XETRA:DR0
|
0.070x |
Annual Cash Flow Conversion Efficiency for Viromed Medical AG (2021–2024)
The table below shows the annual cash flow conversion efficiency of Viromed Medical AG from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see Viromed Medical AG stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €201.16 Million ≈ $235.17 Million |
€-6.03 Million ≈ $-7.04 Million |
-0.030x | +94.36% |
| 2023-12-31 | €64.28 Million ≈ $75.15 Million |
€-34.16 Million ≈ $-39.93 Million |
-0.531x | -60.96% |
| 2022-12-31 | €63.23 Million ≈ $73.92 Million |
€-20.87 Million ≈ $-24.40 Million |
-0.330x | +40.80% |
| 2021-12-31 | €39.97 Million ≈ $46.73 Million |
€-22.29 Million ≈ $-26.06 Million |
-0.558x | -- |
About Viromed Medical AG
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.